Stock 2171 CARSGEN THERAPEUTICS HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:08 27/06/2024 pm IST 		5-day change 1st Jan Change
4.9 HKD -1.21% Intraday chart for CARsgen Therapeutics Holdings Limited -14.93% -24.62%
10:38am CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78% MT
15/06 CARsgen Therapeutics Holdings Limited Presents First-In-Human Results of GPRC5D Targeting CAR-T CT071 At EHA 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%
CARsgen Therapeutics Holdings Limited Presents First-In-Human Results of GPRC5D Targeting CAR-T CT071 At EHA 2024
Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting
CARsgen Therapeutics Holdings Limited commences an Equity Buyback Plan for 57,564,391 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2024.
CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting
Catalyst Pharmaceuticals Names Richard Daly as Chief Executive
CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival
CARsgen Therapeutics Holdings Limited Announces Collaboration Agreement for Zevor-Cel Commercialization in Mainland China with Huadong Medicine
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2171 Stock
  4. News CARsgen Therapeutics Holdings Limited
  5. Other languages